Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp > PRC Partners (June 2022)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Post by Turtle4on Feb 27, 2024 10:21am
162 Views
Post# 35901229

PRC Partners (June 2022)

PRC Partners (June 2022)takes a little longer, huh?

PRC Partner statement from June 2022:
AbbVie is already in the advanced stages of its development and commercialization process for TFC-1067. While we agree with the assessment that it might still take a few months for the company to be ready to release a commercial product based on the compound, we can’t stress enough the potential impact of that product and the revenue it would generate for Sirona Biochem through royalty payments.

https://57ea05b9-8ae7-4fa0-b2d8-87d70d135d8c.usrfiles.com/ugd/57ea05_4dfabf8ca3aa4f9e929d16bcfcc954dd.pdf
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities